The clinical performance is complex and often involves multiple systems. Early identification and standardization of the diagnosis is essential for improving the prognosis. The diagnosis of the disease requires a combination of clinical performance, imaging, laboratory testing and pathological activation.
The platform can help align a team of authoritative experts at home and abroad to provide accurate diagnosis and treatment programs. In recent years, with the development of therapeutic, immune-regulatory therapy and precision medicine, significant improvements have been made in many previously difficult-to-treat genetic metabolic diseases. Treatment needs to be closely monitored for efficacy and adverse reactions, adapted to the timely schedule of disease changes.
Multidisciplinary collaboration (MDT) is particularly important for the comprehensive management of the VLCAD deficiency of long-chain alkylated coenzyme A deoxygenase. 2. Visiting China: arranging face-to-face treatment with authoritative experts, developing individualized treatment programs; 3.
Full-service: providing one-stop services such as medical translation, medical care, accommodation arrangements; 4. Long-term follow-up: establishing a chronic disease management archive, continuous monitoring of disease changes and treatment effects.